It has been another challenging year for the global life science industry. The ongoing economic crisis in Europe as well as pricing pressures from successive governments have hit profitability hard, whilst the industry's reputation has attained new lows on the back of a perceived lack of transparency in clinical trial reporting. Yet opportunities for the industry abound–in the fast emerging markets beyond the BRICs, including Africa, in capitalising on the potential of personalised medicine, and in harnessing ‘the power of networks’ to transform R&D. How will the industry rise to the challenge?

The FT Global Pharmaceuticals and Biotechnology Conference is Europe’s pre-eminent industry event attended by leading executives, government decision makers, investors, analysts and other specialist providers. It provides a unique platform to present new perspectives,’ feel the pulse’ of the industry, and network with peers across the sector.

A selection of photographs taken at this year's event can be found on our flickr page >>